“Mutational Analysis of Bile cfDNA for the Early Diagnosis of Biliopancreatic Tumors”
“Genomic Profiling and Disease Monitoring Using Plasma Cell-Free DNA in Acute Myeloid Leukemia”
“ctDNA Analysis to Understand Resistance and Response to ORC Therapy in EGFR Mutant Non-Small Cell Lung Cancer”
“Liquid Biopsy in Suspected Lung Cancer Solitary Pulmonary Nodules”
“Molecular measurable residual disease (MRD) monitoring by high-throughput techniques in patients with CART 19 therapy”
“HRD biomarker: Qualification and implementation of validated local HRD test”
“Comprehensive molecular characterization of early stage NSCLC with KRAS G12C mutation using ODxET”
“Prognostic value of minimal residual disease monitoring by comprehensive next-generation sequencing in pediatric acute myeloid leukemia”
“Characterizing Prostate Cancer Plasticity Relative to Lethal Disease, Neuroendocrine Differentiation and Therapeutic Resistance”
“Ultrafast next generation sequencing: Universal Testing Of Patients with Infiltrating Adenocarcinomas of the Lung”
“Homologous recombination deficiency (HRD) testing in high-grade serous carcinoma using peritoneal effusion samples”
“TCR repertoire in combination with HLA and TMB as predictor of response to immune checkpoint blockade in melanoma and lung cancer”
“Dissecting the tumor immune microenvironment of breast cancer during pregnancy”
“Analyses of the role of immune-host cell interactions in defining different brain metastases patterns in NSCLC”
"Predictive biomarker for metastatic melanoma patients treated with immune checkpoint inhibitors"
Head Researchers:
Beatriz Bellosillo - Head of Molecular Diagnostics Section, Pathology Department
Edurne Arriola - Head of the Thoracic and Genitourinary Section
“Receiving the grant from Thermo Fisher to assess the role of liquid biopsy in Small cell Lung cancer will allow to discover novel biomarkers and therapeutic avenues in a disease with urgent clinical needs.”
Head Researcher:
Giulia Siravegna, PhD - Instructor in Medicine Harvard Medical School, Department of Medicine, Research staff, Massachusetts General Hospital Cancer Center
“This grant will allow the characterization of circulating free tumor DNA (ctDNA) isolated from ascites fluid in gastric cancer patients and its comparison it with matched peripheral blood ctDNA, as well as primary tumor samples to identify peritoneal/ascites-specific targets. The use of ascitic fluid as a source for predictive and prognostic biomarkers is itself highly innovative and allows for rapid clinical translation as material is routinely sampled in clinical care.”
Head Researcher:
Leomar Ballester - Assistant Professor, Molecular Genetic Pathology and Neuropathology
Co-Director, Molecular Diagnostics Laboratory, Department of Pathology and Laboratory Medicine, Department of Neurosurgery
“The Oncomine Clinical Research Grant will facilitate our development of a cerebrospinal fluid liquid biopsy assay to incorporate precision medicine strategies in the management of patients with primary and metastatic central nervous system tumors. The Genexus System could provide the necessary sensitivity and specificity to enhance current methods for evaluating the potential of targeted therapies for patients.”
Head Researcher:
Professor Stephen Fox - Director of Pathology and Head of the Molecular Pathology Laboratory, at Peter Mac in Melbourne, Australia
"This grant will enable us to provide circulating tumour (ct) DNA testing to patients with non-small cell lung cancer in rural and remote parts of Victoria, Australia, where outcomes are poorer for this cancer. We will be able to rapidly identify mutations in ctDNA and deliver coordinated specialized oncology care to these patients. The goal is to determine whether liquid biopsies can replace tumour biopsies for selecting patients for the most appropriate treatment."
“Clinical validation of a rapid NGS-based molecular screening assay for myeloid neoplasms”
“New detectable targets in liquid biopsy samples of pediatric
brain tumors”
“Rapid in-house comprehensive genomic profiling to guide community oncology practice”
“Evaluation of the prognostic and predictive significance of fusion genes in epithelial ovarian cancer”
